Synairgen plc is the holding company for Synairgen Research Limited, a drug discovery and development company focused on developing therapies which address the causes, rather than the symptoms, of respiratory disease. As at June 30, 2008, the Company’s programmes were IFN-beta, protein, collaboration and other research programmes. IFN-beta is for the treatment or prevention of exacerbations (attacks) of asthma and chronic obstructive pulmonary disease (COPD) caused by the common cold.
(Source: ARS)
